Ildong to conduct clinical trials to develop IMDs
Published: 2012-03-21 06:57:00
Updated: 2012-03-21 06:57:00
Ildong Pharmaceutical Co. has unveiled its plan to develop seven incrementally modified drugs (IMDs) this year, while undertaking the clinical trials of Cotromvix (clopidogrel + asprin), a dual-purpose drug to treat two different conditions.
With less content of aspirin (81 mg), Cotromvix is e...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
